Herincar-Pd1 Cells
PD-1 Antibody
Ningbo Cancer HospitalCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the PD-1 Antibody cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
L-Dep Beijing Friendship Hospital | Phase 3 | B |
Tislelizumab Sun Yat-sen University | Phase 2 | B |
Carboplatin Sun Yat-sen University | Phase 2 | B |
Rivoceranib Jiangsu HengRui Medicine Co., Ltd. | Phase 2 | CCC |
Same molecule, other indications
Herincar-Pd1 Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →